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ABSTRACT 
Salmonella sp. are versatile bacteria that survive and replicate in a plethora of environmental 
niches and hosts, including humans. The illnesses caused by various serovars in humans 
range from mild gastroenteritis to severe systemic disease such as typhoid fever that still 
cause an important number of casualties especially in developing countries. Salmonella 
enterica serovar Typhimurium is the research model for typhoid fever and has provided many 
valuable insights into the molecular pathogenesis of salmonellosis. Its ability to cause disease 
relies on expression of specific virulence factors, often coded for by distinct genomic entities 
termed “Salmonella pathogenicity islands” (SPIs). The invasion of the intestinal lining is 
mediated by SPI1, while SPI2 enables the bacteria to survive, replicate and disseminate in the 
host inside phagocytes. Both SPI1 and SPI2 code for two distinct type three secretion systems 
(T3SSs), which translocate into the host cell bacterial effectors that hijack host cells 
functions.  
Resistance to first line antibiotics has been reported in attempts to treat salmonellosis, even 
extended spectrum –lactamase resistance. Hence, there is a need for new treatment 
alternatives. We report in Paper I a new antimicrobial property of the proton pump inhibitor 
omeprazole, which interfered with SPI2-mediated intracellular replication of S. Typhimurium 
in RAW264.7 murine macrophages. Its effect was bacteriostatic and manifested if the 
compound was applied at early stages of infection. Along with interference with bacterial 
virulence, omeprazole also posed a strong anti-inflammatory effect on macrophages. In 
Paper II we further characterized the immunomodulatory effect of omeprazole, alone or in 
combination with INP0010, another small molecular virulence inhibitor previously shown to 
inhibit the activity of SPI1 and SPI2 T3SSs. The two compounds had either antagonistic or 
synergistic effects on bacterial virulence and on host cell responses such as expression of 
inducible nitric oxide synthase (iNOS), nitric oxide (NO), pro-inflammatory cytokines and 
reactive oxygen species (ROS), depending on the dose and the model of infection used. 
Notably, in contrast to omeprazole, INP0010 enhanced the inflammatory responses of 
macrophages including NO production and hence part of its inhibitory effect on bacterial 
intracellular replication might be due to up-regulation of NO in infected cells.  
Paper III reveals that bacterial thioredoxin 1, a reductase important for maintaining protein 
redox homeostasis, contributes to virulence of S. Typhimurium by participating in the activity 
of SPI2 T3SS. SPI2 and thioredoxin 1 had a convergent contribution to intracellular 
replication of S. Typhimurium both in vitro and in vivo. Catalytic as well as non-catalytic 
functions of thioredoxin 1 appeared important contributors to S. Typhimurium virulence, 
depending on the infection model used.  
The outcome of the infection at individual cell level is dictated by the ever oscillating balance 
between host cell antimicrobial responses and the ability of bacteria to overcome them. In 
Paper IV we show that phagocytes infected with S. Typhimurium have a heterogeneous 
pattern of iNOS expression, which is not dependent on active virulence proficient bacteria 
and that the majority of infected cells are iNOS irresponsive, both in vitro and in vivo. Our 
study underlines the need of shifting from bulk to individual cell analysis when studying 
host-pathogen interactions. 
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1 INTRODUCTION 
1.1 SALMONELLA AND SALMONELLOSIS 
Salmonella is a Gram-negative, rod shaped, facultative intracellular bacteria very closely 
related to Escherichia, with whom it shares 90% of the genome. The divergence of the two 
bacteria from a common ancestor apparently has occurred around 100 million years ago. 
Since that event Salmonella have acquired by horizontal gene transfer multiple virulence 
determinants that contributed to the adaptation of bacteria to different environmental 
conditions, including colonization, invasion, persistence and spread in different hosts. The 
main evolutionary phases of host adaptation were acquisition of genes that confer the bacteria 
invasion capacity, followed by colonization of deeper tissues and ultimately adaptation to a 
wide range of hosts including warm-blooded vertebrates [1, 2].  
The taxonomy of Salmonella is complicated and still evolving. Based on molecular methods 
it has been established that the genus Salmonella has three species, S. bongori, S. enterica and 
S. subterranea [3, 4]. While S. bongori is a pathogen of cold-blooded animals, S. enterica can 
infect and cause disease in a broad range of hosts from nematodes to humans and is further 
divided in 6 subspecies, S. enterica subsp. enterica, S. enterica subsp. salamae, S. enterica 
subsp. arizonae, S. enterica subsp. diarizonae, S. enterica subsp. houtenae and S. enterica 
subsp. indica. S. subterranea was isolated from a low pH, nitrate and uranium contaminated 
sediment and was recently approved as the third Salmonella specie [5].  
The different subspecies are further classified based on the O (somatic) antigen into more 
than 50 serogroups; moreover, the combination of O and H (flagellar) antigen repertoire gives 
rise to over 2400 serovars. Additionally, the presence of Vi (capsular) antigen provides 
another mean of classification of the different serotypes. Most of the human-associated 
serovars belong to S. enterica ssp. enterica [3]. 
Despite the increase in sanitation over the last century there are still high numbers of 
salmonellosis cases all over the world [6-8]. The disease is usually contracted via the faecal-
oral route, by ingestion of contaminated water, various foods such as vegetables and animal-
derived products or by contact with pets [9-17]. Based on disease manifestations Salmonella 
serovars are categorized as typhoidal and non-typhoidal (NTS) [8, 18].  
Typhoid fever, also called enteric fever, is caused by the human restricted serovars Typhi and 
Paratyphi [6, 18] with the infection dose ranging between 103-109 bacteria. This is a serious 
invasive life-threatening disease, which is endemic in the developing countries that still lack 
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appropriate sanitation and clean water supplies. Its clinical manifestations include high fever, 
abdominal pain, nausea, diarrhoea, headache, rash, anorexia and dry cough [19, 20] and it is 
estimated to affect around 27 million people annually, causing more then 200 000 deaths 
[6, 7, 21]. 2-5 % of the typhoid fever patients remain chronically infected and become 
carriers and spreaders of the bacteria even thought they don’t have the symptoms of the 
disease anymore [20]. In this stage the bacteria are primarily located in the gallbladder and 
the biliary tract [22]. 
In contrast to typhoid fever, NTS salmonellosis in humans are reported all over the world, 
with an estimation of 93.8 million cases and 155 000 deaths in the developing countries 
annually [8]. The infection dose varies between 106-109 bacteria and the usual manifestation 
of NTS infection is a self-limited gastroenteritis with watery diarrhoea, nausea, vomiting and 
fever. In some NTS cases, often in immunodeficient patients, the bacteria can cause 
bacteraemia and systemic infection with symptoms similar to typhoid fever [23]. NTSs can 
be caused by many serovars that are not restricted to a specific host, such as Typhimurium, 
Enteritidis, Dublin and Cholerasuis [21]. 
 
Figure 1. The stages of Salmonella pathogenesis 
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A simplified scheme of salmonellosis pathogenesis is depicted in Figure 1. The bacteria 
reach the host by the oral route, survive the gastric acid barrier then colonize the lumen of the 
small intestine and predominantly at the Peyer’s patches (PP) attach to and invade the mucosa 
of the small intestine. The intestinal epithelium is breached by either one of the following 
means, i) engulfment by intraluminal dendritic cells (DCs); ii) bacteria-mediated invasion of 
specialized M cells or iii) bacteria-mediated invasion of ordinary intestinal epithelial cells 
[24-30]. After crossing the epithelium NTS strains usually cause a local inflammatory 
response that leads to infiltration of polymorphonuclear leukocytes (PMNs) and ultimately 
diarrhoea. In contrast, the initial invasion of the intestinal mucosa by typhoidal strains 
usually does not cause a high inflammatory response [21, 31-34]. After gaining access to 
the underlying lymphoid tissues bacteria are taken up by phagocytes (macrophages, DCs, 
neutrophils) and use this intracellular niche for survival, replication and dissemination 
throughout the reticuloendothelial system [34, 35]. In order to accomplish all the above the 
bacteria express several virulence factors that will be detailed in chapter 1.3.3. 
 
1.2 PREVENTION AND THERAPIES 
1.2.1 Prevention 
The first line of salmonellosis prevention is increasing sanitation and hygiene, safe food, 
clean water supplies and better diagnostics for early detection [36]. Along with these, 
vaccination represents the additional tool for prevention of typhoid fever. There are three 
available vaccines against S. Typhi, a killed whole cell-typhoid-parathyphoid A and B 
parenteral vaccine [37], the Ty21a live attenuated oral vaccine [38] and a Vi polysaccharide 
capsule-based vaccine [39, 40]. The first whole cell-typhoid-parathyphoid A and B vaccine 
[37] was effective but had strong side effects. Therefore its use is now very limited. The 
Ty21a live attenuated and the Vi polysaccharide capsule vaccines are safer and have a 
similar moderate effectiveness of approximately 70% in older children and adults for about 
3 years after vaccination. A booster dose is recommended every third year. While the 
Ty21a vaccine is licensed for children over 5 years old, the Vi-polysaccharide vaccine can 
be used for pre-school children older than 2 years [41-50]. To overcome the lack of 
protection for children under 2 years old, a new conjugated Vi vaccine (Vi-rEPA) is in 
current development [42, 51]. 
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Since the killed whole cell-typhoid-parathyphoid A and B parenteral vaccine is not used 
anymore due to safety reasons, there are no other available vaccines against S. Paratyphi 
and the S. Typhi vaccines provide very little cross-protection [40].  
Regarding NTSs there are vaccines against S. Enteritidis and S. Typhimurium [21, 52] that 
are effective in poultry, but not in humans or other hosts. 
 
1.2.2 Treatment and antibiotic resistance 
Due to severity and life-threatening aspects of typhoid fever the treatment with antibiotics is a 
must and it is started as soon as the diagnosis is made.  
Antibiotics started to be used since the middle of the 20th century both in human and 
veterinary medicine and their use has dramatically decreased the death rates in many 
infectious diseases. Due to selective pressure, only a few years after antibiotics were being 
largely used, antimicrobial resistance emerged in many bacteria. The resistance is acquired 
either by endogenous spontaneous mutation or by horizontal transfer of resistance genes 
harboured by mobile genetic elements such as plasmids.  
The golden standard for typhoid fever treatment until mid-1970s was chloramphenicol, which 
reduced the mortality from 10% to less than 2% in developed countries [53, 54]. 
In 1972 the first epidemic due to emergence of chloramphenicol resistant strains occurred in 
Mexico, followed in the next years by several outbreaks in locations from Central America, 
Indian subcontinent and South-East Asia [53, 55-57]. The resistance was thought to be due to 
acquisition of a plasmid that harbours the chloramphenicol acetyl transferase gene from 
Escherichia coli. 
Chloramphenicol use was replaced by ampicillin and trimethoprim in patients infected with 
chloramphenicol resistant strains [58]. Yet, already in 1989 strains of S. Typhi resistant to 
chloramphenicol, ampicillin and trimethoprim emerged in several developing countries and 
termed multidrug-resistant (MDR) strains. The multi-resistance was encoded on a plasmid 
from H1 incompatibility group [59-64]. 
In the early 1990s fluoroquinolones started to be used and the drug of choice was 
ciprofloxacin, especially for endemic regions of MDR S. Typhi and for patients that 
travelled to those areas [58, 63, 65]. Already in 1991 cases of MDR strains resistant to 
ciprofloxacin emerged [63, 66, 67] and since then ciprofloxacin and nalidixic acid 
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resistance has been reported [63, 68]. The resistance to these drugs is due to mutations in 
the DNA gyrase (gyrA or gyrB) or topoisomerase (parC and parE) genes and also due to 
decreased permeability and efflux of the compounds; quinolones resistance has been 
recently proved to be transferred also by plasmids carrying the qnr gene [69, 70]. 
The antibiotics largely used after the emergence of fluoroquinolone resistance are the 
cephalosporins, which belong to the -lactams class of antibiotics. Acquisition of plasmid-
encoded extended spectrum -lactamase lead to resistance to -lactams, initially in NTS 
strains, but recently resistance to the third-generation cephalosporin ceftriaxone has been 
noted even in S. Typhi [71]. 
In humans, an NTS infection does not require antibiotic treatment, only when 
complications such as bacteremia and systemic spread of the bacteria occur or for risk 
groups such as infants, elderly and immunocompromised patients. Moreover, it has been 
shown that the use of antibiotics prolongs the time when the bacteria are excreted, in 
recovery after NTSs [21, 72]. NTS gastroenteritis is usually self-limited and only in severe 
cases fluids and electrolyte replacement is needed. 
However, since the symptoms of NTS infections are common to other bacterial infections 
and in some locations from developing countries the diagnostics methods are not always 
available, antibiotics are misused for NTSs. Antibiotics are also used for treatment of 
salmonellosis in cattle, pigs and poultry when other treatments fail. Therefore the NTS 
strains constitute a reservoir of continuously evolving antimicrobial resistance that can be 
transferred to typhoidal strains. 
 
1.2.3 New therapeutic strategies and chemical genetics 
A drawback of antibiotic usage is the induction of a strong selective pressure in bacteria that 
eventually leads to acquisition of resistance, not only among pathogens but also amongst the 
normal commensal flora. Therefore we are facing now an urgent need of new therapeutic 
strategies to combat infectious diseases.  
One such approach is represented by “chemical genetics”. Even though the concept is old 
and has been mainly used in the context of eukaryotic biology, in the last decade it is more 
and more utilized to describe the use of small molecular compounds that interfere with the 
expression or function of specific virulence factors possessed by pathogenic microorganisms 
[73, 74].  
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Application of such compounds that are not lethal to the pathogen but rather disarm it would 
substantially decrease the selective pressure so that acquisition of resistance would 
dramatically decrease. Moreover, since they target specific virulence-associated traits they 
would not affect the avirulent commensals. 
For instance, one virulence factor that is conserved among several Gram-negative pathogens 
is the type 3 secretion system (T3SS), which will be detailed in chapter 1.3.3. Up to date there 
are several reports of small compounds that interfere with T3SS-mediated virulence in 
pathogens such as Yersinia pseudotuberculosis [75, 76], Chlamydia trachomatis [77] and 
Shigella flexneri [78]. In S. Typhimurium compounds such as selected salicylidene 
acylhydrazides [79-81], a thiazolidinone [82] and the proton pump inhibitor omeprazole [83] 
have been shown to inhibit T3SS-mediated virulence.  
Another example is the small molecule virstatin that interferes with adhesion and toxin 
expression of Vibrio cholerae [84]. 
Although most of these compounds have physicochemical properties that need to be 
improved before being used in clinical studies and become established treatments, they are 
promising candidates in the attempt of switching from antibiotics to virulence blockers in 
infectious diseases treatment. Additionally, they represent valuable tools to be used in on 
going research investigations of pathogens. 
 
1.3 SALMONELLA ENTERICA SEROVAR TYPHIMURIUM - THE RESEARCH 
MODEL FOR TYPHOID FEVER 
The best-characterized S. enterica serovars are Typhi and Typhimurium. As mentioned 
previously, S. Typhi is human restricted and causes the systemic disease typhoid fever, while 
S. Typhimurium has a broad range of hosts ranging from amoebae to man. Most of the details 
of the molecular pathogenicity in Salmonella infection have been discovered from studies of 
S. Typhimurium infection in cell culture settings and mouse models.  
 
1.3.1 Mouse models 
The mouse models have been instrumental for detailing systemic bacterial infections because 
S. Typhimurium causes in mice an infection that apparently parallels S. Typhi infection in 
humans [85]. Also, the possibility to apply gene “knockouts” has brought in the opportunity 
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to study the infection in hosts lacking selected factors, such as inducible nitric oxide synthase 
(iNOS) or phagocyte NADPH oxidase (phox).  
BALB/c is the most widely used mouse strain for investigating S. Typhimurium infections. 
These mice have an innate susceptibility to several pathogens as compared to other strains. 
This is thought to be due to low production of interferon gamma (IFN-) and a preferential 
Th2-type cytokine response, which is important for resistance to extracellular pathogens [86]. 
They also lack functional Nramp1 that makes them less capable of hindering intravacuolar 
bacterial replication [87, 88]. 
To analyse visceral dissemination, mice are typically infected per orally [89]. With a 
reasonable high infection dose (108 bacteria or so) bacteria can be detected in the PP one day 
post infection. The pathology of the small intestine resembles much the one caused by S. 
Typhi in humans; enlarged PP, thickening of the ileal mucosa and a diffuse enteritis that is 
mainly localized at the terminal ileum and PP, while the other areas on the intestinal 
epithelium are mainly intact. Further on, bacteria spread to mesenteric lymph nodes (mLN), 
liver and spleen where they multiply in professional phagocytes such as macrophages. 
Several days after infection bacteria can reach 109-1010 colony forming units (CFUs) per 
organ, causing hepato- and splenomegaly. Bacterial multiplication at these sites causes acute 
abscesses that gradually become enlarged and transform in granulomata that have 
mononuclear leukocytes peripherally and are centrally necrotized [85]. The lesions of the 
hepatic tissue due to inflammation ultimately lead to death of the animal. 
As rodents do act as a natural host of S. Typhimurium, this model is considered to be less 
“artificial”. Yet, it has it’s own limitations. Naturally, S. Typhimurium causes in humans 
enteritis rather than typhoid fever and hence humans and mice mount different host responses 
to infection with this serovar. Also, there are virulence genes present in S. Typhi but absent in 
S. Typhimurium and vice versa.  
Nevertheless the strengths of this model outweigh the drawbacks; it has been and still is a 
very useful model to discover and study major bacterial virulence factors [90] and to test 
typhoid fever vaccine candidates [91]. 
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1.3.2 Cell culture models 
In vitro cell culture models revealed many aspects of the molecular pathogenesis of 
Salmonella infection. They represent very simplified models that brought in light small but 
important pieces of the “puzzle” that is the complex interaction of the pathogen with the host 
cells within the progression of the infection.  
Table 1. Cell lines commonly used in Salmonella research (adapted from Hurley et al., 2003 
[92] and ATCC collection data). 
Name of cell 
line  
Provenience Advantages Disadvantages 
CaCo2 Human epithelial 
colorectal 
adenocarcinoma 
Can form polarized confluent 
monolayer that resembles the 
enterocytes of the small intestine 
 
Do not always grow as readily  
Difficult to transfect 
HeLa Human epithelial 
cervix 
adenocarcinoma 
Human provenience 
Robust in culture 
Not of intestinal origin 
Aberrant karyotype 
Easily contaminates other cell 
cultures 
 
HT29 Human epithelial 
colorectal 
adenocarcinoma 
Can form polarized confluent 
monolayer 
Heterogeneous, contain a small 
subpopulation of mucus-secreting 
cells and columnar absorptive cells 
 
MDCK Canine epithelial 
kidney 
Can form polarized confluent 
monolayer 
Suitable transfection host 
Not of human or mouse origin 
Not of intestinal origin 
 
T84 Human epithelial 
colorectal 
carcinoma 
Can form polarized confluent 
monolayer 
Do not always grow as readily  
Difficult to transfect 
 
J774-A.1 Murine reticulum 
cell sarcoma, 
macrophage 
Phagocytosis capable 
Suitable transfection host 
Robust in culture 
Mouse origin 
 
 
RAW264.7 Murine Abelson 
leukaemia, 
macrophage 
Phagocytosis capable 
Permissive for Salmonella 
intracellular growth 
Suitable transfection host 
Robust in culture 
Mouse origin 
 
 
THP-1 Human monocytic 
leukaemia, 
monocyte 
Suitable transfection host 
Human origin 
 
 
Bacteria-mediated invasion of epithelial cells has been studied using immortalized epithelial 
cell lines such as HeLa, Caco2, HT29, MDCK and T-84 [89, 92, 93]. Macrophage cell lines 
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such as RAW264.7 and J774-A.1 have been instrumental to investigate the details of the 
intracellular stage of Salmonella pathogenesis and its interplay with the host [89, 94]. Table 1 
summarizes some features of commonly used cell lines important in the context of 
Salmonella research. 
The experimental method widely used for in vitro cell culture infection experiments with S. 
Typhimurium is the gentamicin protection assay. Typically, for assays using epithelial cell 
lines the bacteria are grown prior to be applied to cell monolayers in conditions that promote 
expression of virulence factors that mediate the invasion. After application of bacteria to the 
cells bacterial invasion is let to occur for 15 min – 1 hour, after which gentamicin is applied. 
This antibiotic does not penetrate intact eukaryotic cells; therefore the bacteria that are 
located intracellular are protected by its killing action. When studying intracellular phase of 
Salmonella within macrophages, non-invasive bacteria are applied to cells, and similarly after 
they have been phagocytosed by macrophages gentamicin is applied to kill the remaining 
extracellular bacteria and protect the ones that have been internalized. At desired time points 
after the infection the numbers of intracellular bacteria are determined by counting the CFUs 
from the cell lysates plated on Luria Bertani (LB)-agar plates [89, 95]. 
 
 
Figure 2. Immunofluorescence microscopy of two widely used cell lines 16 hours post 
infection with GFP-expressing S. Typhimurium by the gentamicin protection assay. 
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1.3.3 Virulence factors 
S. Typhiurium and S. Typhi share about 89% of the genes while the differences include 479 
genes that are unique to Typhimurium [96] and 601 genes unique to Typhi [97] (Figure 3). 
The differences include virulence genes belonging to the Salmonella pathogenicity islands 
(SPIs), the Vi polysaccharide capsule, plasmids, prophages and phage remnants.  
In Salmonella many virulence-associated genes are clustered in distinct genomic regions 
termed “Salmonella pathogenicity islands”, or SPIs. These regions are usually found next to a 
tRNA gene and differ from the rest of the genome in their lower G+C content, suggesting that 
they were acquired through horizontal gene transfer. Currently there are 21 known SPIs in 
Salmonella serovars; S. Typhimurium and S. Typhi share 11 SPIs (1-6, 9, 11, 12, 13 and 16) 
[98].  
 
Figure 3. S. Typhimurium and S. Typhi share the majority of their genome, including several 
virulence factors. Yet, they do have unique genes that might explain the differences in host 
tropism and disease manifestations (adapted from Sabbagh et. al, 2010 [98]). 
 
SPI1 and SPI2 are considered the hallmarks of virulence in both serovars. They both encode 
an extraordinary supra-molecular secretory apparatus that is the T3SS. Similar T3SSs are 
found in several Gram-negative pathogens [99] and they are evolutionary related to the 
flagella apparatus. Their function is to translocate bacterial effector proteins into host cells 
that will interfere with host functions and enable bacterial invasion, survival and 
dissemination in the host [100]. Visualization of T3SS structure reveals a syringe like 
appearance, with a wide base embedded in the bacterial membrane and a thin extracellular 
needle [101]. T3SS has a size of approximately 3.5 MDa and is composed of around 20 
protein components that are forming the inner membrane export assembly, the basal body 
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that is a hollowed shell which spans the inner and outer bacterial membrane, the extracellular 
needle and the translocon complex that is creating the contact with host cell membrane and 
allows translocation of effectors [102] (Figure 4). The assembly and function of T3SSs are 
tightly regulated. 
 
 
 
Figure 4. Schematic representation of T3SS (based on Galan et al., 2001 [102]) 
 
1.3.3.1 SPI1 
SPI1 is a 40 kb cluster that codes for genes mainly involved in the invasion of the intestinal 
epithelial lining [103]. The genes of the structural components and primary effectors of SPI1 
T3SS are encoded by three operons; the prg/org and inv/spa operons that code for the needle-
like machinery and the sic/sip operon that codes for the translocon and several protein 
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effectors. Apart from the ones encoded by SPI1, Salmonella also secretes via SPI1 T3SS 
proteins coded by other loci than SPI1. Along with these main components, SPI1 encodes 
also regulators such as HilA, HilC, HilD and InvF and chaperones that stabilize and protect 
the effector proteins from degradation and undesired interactions [104, 105].  
SPI1 is induced by the conditions that prevail in the small intestine microenvironment, such 
as low oxygen, high osmolarity, neutral to alkaline pH and presence of bile [106]. In order to 
invade, the bacteria attach to the intestinal epithelial surface using fimbriae and adhesins. 
Subsequently, SPI1 T3SS is assembled and more than 19 bacterial effectors are delivered into 
the host cells. The result of the interaction between the effectors and the host is the bacterial 
uptake by the non-phagocytic cells of the small intestine epithelial lining. This is achieved by 
effector-mediated induction of actin cytoskeleton rearrangements and membrane ruffling 
followed by internalization of the bacteria. The main bacterial effectors involved are SipA 
[107] and SipC [108] that bind actin, induce its nucleation, polymerization and stabilize the 
F-actin filaments. SopE, SopE2, SopB interact with and activate the Rho family GTPases 
Cdc42 and Rac1, central regulators of the host cell actin cytoskeleton, and that subsequently 
leads to rearrangements of the actin filaments and formation of membrane ruffles [102, 109, 
110]. After bacterial uptake by the host cell the activation of the Rho family GTPases and the 
actin cytoskeleton rearrangements are reversed by the action of the effector SptP that 
inactivates Rac-1 and Cdc42 [111].  
Another feature following invasion is the induction of an inflammatory response followed by 
infiltration of PMNs. This is also due to activation of Rho GTPases that trigger several 
mitogen-activated protein kinase (MAPK) pathways and activate the transcription factors 
NF-kB and AP-1 that direct the production of pro-inflammatory cytokines such as IL-8 
[112]. Other SPI1 effectors such as SopA, SopD and SipA as well as secreted flagellin 
further contribute to inflammation by stimulation of PMNs transmigration, induction of 
fluid accumulation and diarrhoea [102].  
The orchestrated induction and function of SPI1 is tightly regulated. The key regulator of 
SPI1 gene expression is HilA [113] and in BALB/c mice deleting hilA results in the same 
phenotype as deleting the whole SPI1 locus [114]. HilA activates the transcription of 
inv/spa and prg/org promoters; subsequently InvF encoded by the inv operon activates the 
transcription of sic/sip operon as well as other genes located outside SPI1. The expression 
of HilA is positively controlled by the regulators HilC and HilD encoded by SPI1, and by 
RtsA encoded outside SPI1 on the chromosome [105]. HilA negatively regulates its own 
expression. Another negative regulator of SPI1 hence HilA, is HilE encoded outside SPI1, 
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which exerts its function through binding to HilD and inhibiting its up-regulating action on 
HilA [115].  
 
1.3.3.2 SPI2 
SPI2 is the second identified pathogenicity island in S. Typhimurium, with size roughly 
similar to SPI1. Its function enable the bacteria to adapt, survive and replicate inside host 
cells, ensuring a successful intracellular life-style which is one of the most remarkable 
features of Salmonella. SPI2 codes for a second T3SS, effector proteins, chaperones and the 
two-component regulatory system SsrA/SsrB [116]. 
After breaching the intestinal epithelial barrier Salmonella serotypes that cause a systemic 
illness are phagocytosed by professional phagocytes such as macrophages, neutrophils and 
dendritic cells that were attracted and concentrated at the site of bacterial invasion as a 
consequence of inflammatory cytokines secreted by the epithelial cells. Once inside the cells 
the bacteria reside initially in a spacious phagosome that tightens up around the bacteria and 
results in a vacuolar compartment called the Salmonella containing vacuole (SCV). The 
conditions encountered by the bacteria in the developing SCV, such as low pH and poor 
nutrient status, are the ones that induce SPI2 [117, 118]. Subsequently SPI2 T3SS is 
assembled at the interface bacteria-SCV membrane and through the needle complex the 
bacteria is able to deliver around 30 effector proteins into the host cell cytosol. In contrast to 
SPI1 effectors, the function of the SPI2 effectors is still poorly understood. A list of the 
effectors secreted by SPI2 T3SS and their function is given in Table 2. Notably, mutants 
lacking some of the individual effectors do not show significant attenuation in mice or in cell 
lines. Therefore, many of them seem to have redundant functions [119]. Several effectors 
secreted by SPI2 T3SS are encoded outside SPI2 [120]. The concerted action of SPI2 
effectors controls the fate of SCV, and the manipulation of host cell factors leads to 
establishment of SCV as a unique intracellular niche that allows bacterial survival and 
growth, quite distinct from a normal phagosome.  
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Table 2. The effectors secreted by SPI2 T3SS (adapted from Haraga et al., 2008 [121]; 
Figueira and Holden, 2012 [122]). 
Effector Function 
CigR Unknown 
GtgA Unknown 
GogB Unknown 
PipB Unknown 
PipB2 Contributes to Sif formation and extension in epithelial cells 
SifA Induces Sif formation in epithelial cells, maintains integrity of the SCV and down-
regulates kinesin recruitment to the SCV 
SifB Unknown 
SopD2 Contributes to Sif formation in epithelial cells and maintenance of SCV integrity 
SpiC Inhibits endosomal trafficking 
SpvB Inhibition of actin polymerization, macrophage cytotoxicity, P-body disassembly in 
infected cells 
SpvC Dephosphorylation of MAP kinase 
SpvD Unknown 
SseF Contributes to Sif formation and microtubule bundling in epithelial cells 
SseG Contributes to Sif formation and microtubule bundling in epithelial cells 
SseI (SrfH) Contributes to host-cell dissemination 
SseJ Maintenance of SCV integrity, deacylase activity 
SseK1 Unknown 
SseK2 Unknown 
SseK3 Unknown 
SseL Macrophage delayed cytotoxicity, down-modulation of NF-kB-dependent cytokine 
production, altered lipid metabolism in infected cells 
SspH2 Inhibits the rate of actin polymerization and contributes to virulence in calves 
SteA Unknown 
SteB Unknown 
SteC Unknown 
SteD Unknown 
SteE Unknown 
 
SCV biogenesis and maturation has been thoroughly studied using different macrophage and 
epithelial cell lines and several studies shown that SCV transiently interacts with early 
endocytic pathway, quickly lose early endosomal markers and gain late endosomal markers 
such as LAMP-1, LAMP-2, LAMP-3, the GTPase Rab7 and the vacuolar ATPase. The SCV 
also excludes M6PR, the receptor that delivers lysosomal hydrolases [123-128]. SCV 
associates with a set of Rab GTP-ases distinct from a typical phagosome and this is correlated 
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with bacterial control of endosomal recycling pathways and continuous remodelling of SCV, 
not only to prevent fusion with undesired endocytic compartments but also to remove 
unwanted factors such as M6PR-positive membrane [128]. The consensus so far has been 
that SCV does not fuse with lysosomes [129, 130], even though other studies have found the 
opposite [131]. Moreover, more recent studies have shown that in HeLa cells SCV 
significantly associates with lysosomes as early as 30 minutes post infection and up to several 
hours after, and proposed that the fusion with the lysosomes is rather delayed than prevented 
[132] or that SCV fuses with enzyme-depleted lysosomes [133].  
The action of SPI2 effectors directs SCV to a perinuclear location proximal to the Golgi 
apparatus, induces host cytoskeleton rearrangements by regulating actin and microtubule 
motors to create a protected "bunker" that allows bacterial replication inside the host cells 
[128]. In macrophages, SPI2 mediates also the bacterial protection against the toxic action of 
reactive oxygen and nitrogen species (ROS, RNS) [134, 135]. 
In epithelial cells another phenotype produced by intracellular Salmonella is the formation of 
Salmonella-induced filaments (Sif), which are formed along microtubule scaffolds. The 
secreted effectors involved in Sif formation are SifA, SseF and SseG [119, 136, 137]. 
SPI2 gene expression is mainly regulated by the two-component regulatory system 
SsrA/SsrB. Conditions like low pH, low osmolarity, low Ca2+ and Mg2+ are sensed by the 
membrane sensor kinase SsrA and the signal is transmitted to the transcriptional activator 
SsrB which induces SPI2 expression [138]. 
 
1.3.3.3 The interplay and regulation of SPI1 and SPI2 
Genetics studies of the two T3SSs suggest they were acquired independently; even so, 
probably the host environments posed a selection pressure that led to their cooperation [102]. 
Although SPI1 and SPI2 are induced and play crucial roles in different phases of Salmonella 
molecular pathogenesis, evidence of crosstalk and overlapping functions for certain effectors 
have been reported. Several SPI1 effectors (SipA, SopA, SopB, SopD and SopE2) persist or 
are expressed in the intracellular phase and add to SPI2 effector functions [139, 140]. For 
example, the SPI1 effector SipA has been detected in association with SCV and seems to play 
a role together with SPI2 effector SifA in directing SCV to the perinuclear location [141]. 
SopB, another SPI1 effector protein is involved in early stages of SCV maturation [142] and 
stimulates NO production in macrophages [143].  
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Likewise, it has been shown in mice infected with S. Typhimurium that expression of SPI2 
T3SS begins in the intestinal lumen even before intestinal penetration, probably to prepare 
the bacteria for the intracellular phase of the disease [144]. Moreover, impairment of the SPI2 
T3SS apparatus decreases the expression of several SPI1 T3SS genes and affects the ability 
of the bacteria to invade epithelial cells [145, 146]. 
Regulation of gene expression in response to environmental stimuli in Salmonella and other 
Gram-negative pathogens is controlled by several two-component systems, which consist of 
a membrane-bound kinase that senses a specific environmental stimulus, and a response 
regulator that activates differential expression of target genes. SPI1 and SPI2 expression is 
also regulated by several two-component systems. 
PhoP/PhoQ two-component system is activated in SCV by low pH and low divalent cations 
and regulates directly or indirectly over 200 genes, including genes involved in intracellular 
survival and growth, invasion, motility and resistance to antimicrobial peptides [147, 148]. 
PhoPQ plays an important role in controlling both SPI1 and SPI2 gene expression. It 
represses SPI1 by down-regulating HilA, but it also actives the SPI1 operon orgBC that is 
expressed intracellularly and might be involved in later stages of the infection [149]. 
Activation of PhoPQ system by the conditions prevailing in the SCV leads to activation of 
SPI2 expression through induction of SPI2 regulator system SsrA/SsrB; PhoP binds to SsrB 
promotor to induce SsrB expression and controls SsrA post-transcriptionally [150]. 
Another two-component system that controls expression of SPI1 and SPI2 genes is 
EnvZ/OmpR, which was initially characterized for sensing osmolarity variations in the 
environment and controlling the expression of the outer membrane proteins OmpC and 
OmpF. OmpR response regulator affects SPI1 expression by inducing hilC expression and 
post-transcriptional HilD activation [105], while regulation of SPI2 is due to OmpR direct 
binding to ssrAB promotors and subsequent induction of their expression [151, 152]. 
SirA/BarA is also an important two-component regulatory system mainly required for SPI1 
induction and bacterial invasion, but also involved in carbohydrate metabolism, motility and 
biofilm formation. It is not known exactly which environmental signals are sensed by the 
sensor kinase BarA. Subsequently, SirA directly binds to hilA and hilC promoters to induce 
their expression [105, 153]. SirA also up-regulates HilD expression post-transcriptionally by 
inducing expression of the two small regulatory RNAs CsrB and CsrC, which bind to CsrA. 
CsrA is an RNA binding protein that binds to hilD mRNA and inhibits SPI1 gene expression 
[154]. 
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1.3.3.4 Spv 
Another important virulence factor of S. Typhimurium that is not present in S. Typhi is the 
spv gene cluster, located on a large plasmid called pSLT. The spv operon contains the spvA, 
spvB, spvC and spvD structural genes, and spvR that codes for a positive transcriptional 
regulator. The spv genes are induced and expressed inside SCV and are important for 
intracellular survival and bacterial systemic dissemination in mice [155]. spvB, spvC and 
spvR are the genes mainly important for the virulence of the spv locus [156]. SpvB is a toxin 
that targets actin and prevents its polymerisation by ADP-ribosylation of actin monomers 
[157], whereas SpvC has phosphothreonine lyase activity and interferes with MAPK 
signalling of infected host cells [158]. Both SpvB and SpvC are secreted by the SPI2 T3SS 
[158, 159]. 
 
1.3.3.5 LPS 
Lipopolysaccharides (LPSs) are the main constituents of the Gram-negative bacteria cell 
wall. In Salmonellae LPS is composed of the glycolipid lipid A that anchors LPS in the outer 
membrane of bacteria, an oligosaccharide core and the polysaccharide O-antigen. LPS is 
conserved among different bacteria species, but the number of acyl chains on lipid A, the 
composition of sugars of the core and the O-antigen confer a high diversity between different 
bacteria. Bacterial strains that are mutated to lack the O-antigen produce a “rough” colony 
morphology on LB agar plates while the ones that have the O-antigen are “smooth” [160]. 
LPS protects the bacteria by conferring membrane stability and resistance to harmful agents 
from the environment including antibiotics and antimicrobial peptides. For pathogenic 
bacteria such as Salmonella, LPS constitutes a virulence factor important in the interplay with 
the host by inducing pro-inflammatory responses and protecting bacterial membrane from 
action of complement membrane attack complex [160-164].  
Depending on the environmental conditions, Salmonella is able to modify its LPS to increase 
bacterial fitness. The major regulators of LPS composition are the PhoP/PhoQ and 
PmrA/PmrB two-component systems [165, 166]. The environmental conditions that are 
detected by the PmrB sensor are high Fe3+, high Al3+ or a mild acidic pH. Subsequently, 
PmrB autophosphorylates and transfer the phosphoryl group to the response regulator PmrA 
that activates expression of genes involved in LPS modification such as pbgP, ugd, pmrC. 
PmrA activation can be also achieved indirectly via the PhoP/PhoQ system that activates 
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expression of PmrD, which is a protein that regulates and promotes PmrA activity post-
transcriptionally [165, 167]. 
 
1.3.4 Host responses and Salmonella’ s solutions 
In order to cause disease Salmonella has to successfully pass several challenges encountered 
inside the host. The first host defence encountered by the bacteria is the acidity of the 
stomach. This condition leads to activation of an adaptive response called the acid tolerance 
response (ATR) [168] which causes expression of acid shock proteins that support bacterial 
survival and passage of the stomach barrier.  
In the small intestine Salmonella encounter challenges like peristalsis, other competing 
bacteria, digestive enzymes, bile salts and especially antimicrobial peptides. It is not entirely 
clear how the bacteria face all these challenges to gain access to the epithelial cells lining of 
the small intestine. Some mechanisms to escape the microbicidal effect of antimicrobial 
peptides are modification of LPS in order to create a more positively charged membrane that 
would reject the positively charged antimicrobial peptides [166, 169] and bacteria-mediated 
down-regulation of antimicrobial peptides such as -defensins and lysozyme [170]. 
Once the bacteria has gain access to the epithelial cells in the small intestine they adhere to 
the cells and induce bacterial internalization mediated by SPI1 T3SS. The host responses 
induced by SPI1 effectors, along with actin cytoskeleton rearrangements that induce bacterial 
internalization, are production of pro-inflammatory cytokines such as IL-8, CXCL1/2/3, 
CXCL5 and CCL2 that leads to recruitment of neutrophils and macrophages to the site of 
infection [171]. These cells actively phagocytose the bacteria that gain access to the lamina 
propria. In turn, the phagocytes further produce other inflammatory cytokines like IL-1, TNF-
, IL-6 and chemoattractants (CCL3/4, CXCL1/2) [112, 121, 171] that leads to recruitment of 
more inflammatory cells and other events associated with acute inflammation. For instance, 
ROS produced by phagocytes upon inflammation react with intestinal thiosulfate and form 
tetrathionate, a new respiratory electron acceptor utilized by S. Typhimurium and which it 
confers a growth advantage over the gut microbiota [172]. The SPI1 effector SipB contributes 
to intestinal inflammation by stimulating production of IL-1 and IL-18 through binding and 
activating caspase-1 [173]. After crossing the epithelial barrier Salmonella actively restores 
the actin cytoskeleton, turn-off MAPK signalling, inhibit NF-kB nuclear translocation and 
subsequently down-regulate cytokine production by the action of the SPI1 effectors SptP, 
SspH1 and AvrA [111, 174-176]. The bacteria-mediated down-regulation of intestinal 
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inflammation in Salmonella pathogenesis might suggest that on a long run the bacteria could 
potentially tend to evolve towards asymptomatic colonization of the small intestine, a feature 
associated with parasitism or commensalism [121]. 
 
1.3.4.1 Salmonella and the phagocytes 
The next stage of Salmonella infection is the intracellular phase where the bacteria face the 
challenges of the intracellular milieu of phagocytes. S. Typhimurium is able to reside in 
phagocytes such as neutrophils, DCs and macrophages.  
Neutrophils harbour bacteria in early stages of infection and constitute a reservoir from 
which bacteria can escape to more permissive cell-types [177]. The mechanisms by which the 
bacteria are able to escape killing by neutrophils are poorly understood. More likely that the 
bacteria are protected from neutrophils actions by residing in cells such as macrophages or 
DCs. 
Salmonella is phagocytosed by DCs in the submucosal tissue and at PP. DCs are phagocytes 
important in antigen presentation and subsequent triggering of adaptive immune responses, 
bridging innate and adaptive immunity. Following uptake of bacteria they migrate to 
secondary lymphoid organs, undergo maturation that includes up-regulation of major 
histocompatibility complex (MHC) and costimulatory molecule expression and then interact 
with T cells. The bacteria prevent antigen presentation by surviving in SCV and avoiding 
lysosomal degradation or by inducing apoptosis by the action of the effector SipB. 
Salmonella is also able to regulate the polyubiquitination and the expression of MHC II on 
the DCs surface, which may reduce the ability of DCs to present antigens to CD4 T cells 
[178]. To circumvent this, uninfected DCs can act as bystander antigen presenting cells and 
engulf antigenic material from neighbour cells that have undergone bacteria-induced 
apoptosis [179]. In vitro studies have shown that another mechanisms by which S. 
Typhimurium killing and processing for antigen presentation can occur is by targeting the 
IgG-coated bacteria to FcRs receptors on the DCs surface [180]. Bacterial internalization by 
this route affects the ability of SCV to avoid lysosomal degradation. While most of the 
bacteria are safe within SCV, a small proportion escape in the cytosol due to damaged SCV 
and failure of bacteria to repair the damage [181]. In the cytosol the bacteria are recognized 
by the autophagy machinery, which leads to degradation of the pathogen by lysosomal 
proteases [182].  
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Even though bacteria prevent T cell activation by DCs in a SPI2-dependent manner [183], T 
cell activation still occurs and has an important role in clearance of the infection [184-186]. 
Apart from the above-mentioned functions of DCs, these cells also produce in response to 
Salmonella infection cytokines that activate and recruit other immune cells such as natural 
killer cells (NK), neutrophils, macrophages and T-cells [186]. Finally, DCs are the major 
contributors to translocation of the bacteria to mLNs, which reduces bacterial dissemination 
to systemic compartments and enables mounting of adaptive immune responses [187]. 
The most studied phagocytic cells that provide the niche for survival and dissemination of 
Salmonella are the macrophages. The capacity to survive inside macrophages is a vital 
requirement of Salmonella virulence both in vitro and in vivo [188]. As described above, 
upon phagocytosis SPI2 effectors divert the natural vacuolar maturation of SCV to prevent 
lysosomal fusion and degradation of the bacteria. The main features of macrophage responses 
to S. Typhimurium infection and the bacterial counteracts are discussed bellow. 
 
1.3.4.2 Oxidative and nitrosative stress 
Apart from the destructive action of lysosomal proteases bacteria also face another challenge 
in the phagocyte intracellular milieu, which is the microbicidal action of ROS and RNS. 
Production of ROS relies on the activity of phox, a multimeric enzyme complex that is 
assembled on the phagosome membrane following phagocytosis. Using NADPH as the 
electron donor, phox reduces molecular oxygen to the superoxide radical (O2-), which 
subsequently dismutates to hydrogen peroxide (H2O2). H2O2 can be further converted to 
hydroxyl radicals (OH) in the Fenton reaction or to hypochlorous acid (HOCl) by 
myeloperoxidase action [189]. Chronic granulomatous disease patients that have a mutation 
in the gp91 phox subunit gene are impaired in ROS production and suffer from recurrent and 
atypical infections, which demonstrates the importance of ROS in controlling infections, 
including NTS infections [190]. 
iNOS is a cytosolic enzyme that catalyses the production of nitric oxide (NO) in a reaction 
where L-arginine is oxidised to L-citruline, in the presence of oxygen and NADPH. NO auto-
oxidation results in production of other RNS such as nitrogen dioxide (NO2), dinitrogen 
trioxide (N2O3) and S-nitrosothiols that have enhanced antimicrobial potential [191]. 
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Effective iNOS inducers are the bacterial LPS as well as pro-inflammatory cytokines IFN-, 
TNF-, IL-1 and IL-2 [192, 193]. LPS stimulation of Toll-like receptor 4 (TLR4) induces 
production of NO as well as production and secretion of the main pro-inflammatory 
cytokines. Upon binding to LPS-binding protein (LBP), LPS is delivered to the high-affinity 
receptor CD14. TLR4 in collaboration with the extracellular protein MD-2 interacts with the 
CD14-LPS complex and via adaptors that include MyD88 and IRAK induce an intracellular 
signalling cascade that leads to activation of MAPK and NF-kB pathways that converge and 
induce iNOS transcription [193]. IFN- induces iNOS transcription by interaction with 
IFNR1-IFNR2 complex that activates Jak-STAT pathway that leads to synthesis of the 
transcription factor IRF-1, which is responsible for stimulation of iNOS induction [194, 195]. 
 
 
Figure 5. Immunofluorescence microscopy of RAW264.7 macrophages 16 hours post 
infection with S. Typhimurium, revealing iNOS expression (A) and ROS production (B). 
 
Phox and iNOS activities synergise. NO can further diffuse across the phagosomal membrane 
and react with superoxide radicals produced by phox to form peroxynitrite (ONOO-) that can 
be further converted to other potent RNS [189]. In vivo studies using gp21phox deficient, 
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iNOS deficient, double iNOS/gp21phox deficient and their congenic wild-type mice as well 
as in vitro studies using peritoneal macrophages from the above mentioned mice strains, 
revealed that phox activity plays an important role in reducing the initial numbers of 
intracellular bacteria at early time points of infection, while iNOS is important to control 
bacterial replication at later stages of infection [196, 197]. Therefore phox and iNOS have a 
delineated temporal action even though their products interact to form potent toxic radicals.  
The toxic effect of ROS and RNS is due to their ability to damage a wide range of microbial 
targets like DNA, RNA, proteins, vitamins and lipids [191, 198-200]. The main antimicrobial 
action of ROS is the induction of DNA base oxidation and strand breaks, several oxidative 
modifications of proteins including oxidation of thiol groups and interaction with the iron-
sulfur clusters of metabolic enzymes, which results in cytosolic iron release that can further 
sustain the Fenton reaction and potentiate ROS production [199, 201, 202]. RNS have also a 
broad spectrum of antimicrobial properties such as inhibition of bacterial respiration, DNA 
replication and specific metabolic pathways like the tricarboxylic acid cycle, as a result of 
their interaction with DNA, protein metal centres and thiols [203-205].  
 
1.3.4.3 Salmonella ROS/RNS stress management 
Salmonella has evolved various evasive, protective and repairing mechanisms in order to 
survive intracellular oxidative and nitrosative stress. Normally upon phagocytosis of 
pathogens, the membrane and cytosolic components of phox are mobilised and assemble to 
discrete cytosolic vesicles, which migrate and fuse with the phagosome. S. Typhimurium 
creates its own “special” phagosome that is SCV and it has been proposed that SCV evades 
the fusion with phox containing vesicles [135, 206] in a SPI2-dependent manner, even though 
more recent studies revealed that phox assembly on SCV occurs even in SPI2-proficient 
bacteria and suggested that Salmonella rather rely on its own arsenal of detoxifying enzymes 
to cope with ROS [207]. These enzymes differ by their location and substrate specificity. The 
periplasmic (SodCI, SodCII) [208] and cytoplasmic (SodA, SodB) [209, 210] superoxide 
dismutases convert O2- to H2O2 that is further degraded to water and oxygen by catalases 
(KatE, KatG, KatN) and peroxidases (AhpC, TsaA, Tpx) [211, 212] in the bacterial 
cytoplasm.  
RNS production of murine macrophages in response to S. Typhimurium infection begins at 
around 6-8 hours post infection [213] (Paper IV-Banesaru et al., Manuscript). It has been 
shown that S. Typhimurium is able to subvert its intracellular co-localization with iNOS by 
  23 
the action of SPI2 T3SS [134]. Moreover, bacteria are able to detoxify NO by the action of 
flavohaemoglobin Hmp, which catalyses the oxygen-dependent denitrosylation of NO to 
nitrate (NO3-) or the oxygen-independent reduction of NO to nitrous oxide (N2O), which are 
less toxic. In the presence of NO Hmp synthesis is significantly up-regulated and hmp 
mutants are impaired in growth both in LB and inside macrophages [214, 215]. Apart from 
Hmp Salmonella possesses other NO detoxifying enzymes such as the flavorubredoxin NorV, 
the periplasmic cytochrome c nitrite reductase NrfA [213, 216] and the glutathione-dependent 
formaldehyde dehydrogenase that can decrease the levels of S-nitrosoglutathione formed 
during nitrosative stress [217]. Constitutive detoxification of NO by thiol-based scavenging 
systems such as the homocysteine, cysteine and tripeptide glutathione is another mean of 
directly removing RNS [218]. 
Apart from avoidance and detoxification of ROS and RNS Salmonella have the capacity to 
repair the damage produced to macromolecules such as DNA and proteins as a result of their 
interaction with the toxic reactive species. DNA repair is conducted by the action of 
RecA/RecBCD and base excision repair (BER) [219-221] systems. The oxidative 
modifications of thiol groups of proteins perturb the redox balance in the bacterial cell, the 
activation status of enzymes and redox-sensitive signal transduction. S. Typhimurium and 
other Gram-negative bacteria are equipped with several oxidoreductases that repair oxidative 
damage and regenerate antioxidants, such as the methionine sulfoxide reductase and the 
thioredoxin, glutathione/glutaredoxin and periplasmic Dsb systems [95, 222, 223].  All these 
reductases use NADPH as the electron source; hence an important role has been attributed 
also to the glucose 6-phosphate dehydrogenase (G6PD) encoded by the zwf gene, which 
catalyses the first enzymatic step in the pentose phosphate cycle that provides reducing 
equivalents in the form of NADPH along with ribose for nucleoside synthesis [224]. 
The coordinated expression of genes responsible for resistance to or repair of oxidative 
damage is performed by the regulatory proteins OxyR and SoxRS [225-228]. Cysteine 
oxidation or S-nitrosylation leads to OxyR activation, whereas SoxR is activated by the 
reversible oxidation of an iron-sulphur cluster. The oxidised proteins can bind to DNA and 
activate transcription of different oxido-protective enzymes. Moreover, the response regulator 
SsrB functions also as a redox sensor; oxidation of o specific cysteine in SsrB increases the 
bacterial fitness in a murine model of Salmonella infection [229]. 
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2 AIMS OF THE THESIS 
 
The focus of the thesis is to explore new potential chemical inhibitors of S. Typhimurium 
virulence and to detail aspects of the interplay between the bacteria and host cells. 
Specifically, the general aims are:  
i. To probe for the ability of commercially available proton pump inhibitors to prevent 
S. Typhimurium intracellular replication 
 
ii. To characterize and compare two small-molecular weight virulence inhibitors in their 
effect on S. Typhimurium intracellular replication and on infected host cells  
 
iii. To establish the role of thioredoxin 1 in S. Typhimurium virulence 
 
iv. To investigate at the level of individual cells the iNOS responses of phagocytes 
infected with S. Typhimurium 
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3 RESULTS AND DISCUSSIONS 
3.1 PAPER I 
Omeprazole antagonizes virulence and inflammation in S. Typhimurium-infected 
RAW264.7 cells 
Chemical interference with expression or function of virulence factors using small-molecular 
compounds falls under the concept of chemical genetics. Such approaches are not only 
providing tools for fundamental research investigations but also have the potential to pinpoint 
new potential strategies and molecular targets for pharmaceutical interference with virulence 
and hence associated disease. Along with low Mg2+, low phosphate, low nutrients level, 
acidification of the vacuolar compartment in which Salmonella resides in is a condition that 
induces SPI2 expression, subsequent T3SS assembly and secretion of the bacterial effectors 
responsible for creating the SCV, a protected niche for propitious survival and growth of the 
pathogen [117, 118]. As mutants defective in SPI2 cannot replicate inside host cells, another 
way of interference with intracellular replication would be to alter the conditions that lead to 
SPI2 induction.  
In Salmonella identification of compounds that target T3SS functionality and resulting 
virulence has given new hopes in the challenge to design new antibiotics in an era endangered 
by the continuous emergence of bacterial strains resistant to available antimicrobials [81, 
230]. Even though most of them still have major physicochemical constrains that makes them 
not suitable to be used in vivo, they still provide a valuable base for further improvements and 
design of new generations of molecules.  
Another important pool to be explored for new pharmaceutical effects, including 
antimicrobial effects, are the compounds that are used as active ingredients in already 
commercially available drugs. The big advantages with this approach is that these compounds 
are safe to be used in vivo since they have already been tested for potential harmful side-
effects and have known ADMET properties (absorption, distribution, metabolism, excretion 
and toxicity). 
Using the above rationale, we set to test the potential use of the proton pump inhibitor 
omeprazole to alter the pH of SCV and in this way interfere with intracellular molecular 
pathogenicity traits of S. Typhimurium. Omeprazole is a benzimidazole compound 
commercially available and widely used in treatment of peptic ulcer that binds irreversibly to 
the H+/K+-ATPase of the stomach parietal cells and in this way suppresses acid secretion. 
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Inhibition of vacuolar H+-ATPase by the macrolide bafilomycin A1 in S. Typhimurium 
infected macrophages have previously generated discrepant reports; while Rathman et al., 
1996 [231] shown that it drastically reduces the intracellular growth of the bacteria, in a later 
study the effect of bafilomycin application on intracellular replication of S. Typhimurium 
differed depending on the cell line used [232].  
We set to test the effect of the two proton pump inhibitors on intracellular replication of S. 
Typhimurium in a cell culture infection model using RAW264.7 murine macrophages and the 
gentamicin protection assay. In our study application of a similar concentration of 
bafilomycin A1 as previously reported resulted in a drastic reduction of intracellular bacteria 
recovered 16 hours post infection. Moreover, bafilomycin reduced the intracellular pool of 
non-replicating bacteria, when tetracycline was added to block the bacterial protein synthesis. 
This implies that bafilomycin imposes a bactericidal effect on intracellular bacteria. 
Omeprazole on the other hand, apart from significantly reducing the intracellular growth of 
bacteria in a dose-dependent manner, had no further diminishing effect on the number of 
bacteria recovered from infected cells treated with tetracycline, indicating that its effect is 
rather bacteriostatic. To further analyse its effect we performed infections of RAW264.7 
macrophages with a variant of S. Typhimurium 14028 bearing a plasmid that besides an 
ampicillin resistance marker has a temperature sensitive replicon. As the bacteria divide at 
37°C the plasmid will segregate and bacterial replication can be measured by the 
determination of the proportion of ampicillin resistant bacteria; the less ampicillin resistant 
progenitors, the more replication rounds. In this experiment, the bacteriostatic nature of 
omeprazole’s effect was supported by its ability to reduce both intracellular bacterial growth 
and the segregation of the plasmid. 
To analyse the kinetics of intracellular bacterial growth we determined the growth yields at 2, 
4, 6, 8, 10 and 16 hours post infection. A net growth was detectable starting with 8 hours post 
infection. Application of omeprazole at the above mentioned time points revealed that its 
growth yield reducing effect occurs if the compound is applied at early time points post 
infection and diminishes if added at later time points. Moreover, its effect was substantial 
even if the cells were only pre-treated with the compound for 3 hours before infection and 
then omitted (data not shown). These results lead us to conclude that the drug is effective 
only if applied before initiation of bacterial replication. Hence it might interfere with the 
virulence factors responsible for promoting and sustaining S. Typhimurium replication inside 
host cells, such as SPI2 [116]. Therefore we next tested the effect of omeprazole on selected 
SPI2 mutants that are strongly (sifA, ssaV) or partially (sseG, sseF) impaired in 
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intracellular replication. ssaV codes for a major component of SPI2 T3SS, whereas sifA, sseG 
and sseF code for secreted effector proteins. The rationale of using these mutants was that if 
omeprazole would have an additional inhibitory effect on the intracellular basal replication of 
ssaV or sifA mutants, it would indicate that the compound acts via a different pathway than 
SPI2; if omeprazole would not add to the replication inhibition of these mutants, it would be 
an indication that it might act through interference with SPI2. The results revealed that   
omeprazole application caused no further decrease in growth for sifA and ssaV mutants, 
which implies that the compound is indeed interfering with SPI2 or SPI2 T3SS. The 
intracellular growth of sseF and sseG mutants was only partially reduced, and application of 
omeprazole further reduced it; this is in accordance with previous reports which shown that 
gene deletion of some SPI2 effectors does not provide full attenuation of virulence and hence 
the function of several SPI2 effectors is redundant [119, 233]. 
Apart from interfering with SPI2, another way by which the intracellular bacterial loads could 
be reduced is due to the microbicidal effect of ROS and RNS produced by macrophages in 
response to infection. Moreover, it has been reported before that bafilomycin [234] and 
lansoprazole [235], a proton pump inhibitor closely related to omeprazole, affect the pro-
inflammatory responses of macrophages. Therefore we tested also in our experimental setup 
the effect of bafilomycin and omeprazole on NO production and pro-inflammatory cytokines 
secretion. Bafilomycin up-regulated NO production of infected cells, whereas surprisingly 
omeprazole inhibited it. Omeprazole also inhibited iNOS expression, delayed IB- 
degradation and decreased the secreted levels of IL-6 and TNF-. These are outstanding and 
ideal properties of a potential new antimicrobial; interference with virulence while down-
regulating the inflammatory activation of the host.  
Besides the different effect on NO production, the two compounds also differently affected 
the viability of macrophages. While bafilomycin increased the proportion of early and late 
apoptotic cells as well as the LDH release of cells, omeprazole had no deleterious effects on 
cell integrity and viability. Hence, the detrimental effect of bafilomycin on cells might 
explain the strong bactericidal effect on intracellular bacteria, by the gentamicin getting 
access to the intracellular bacteria due to damaged cell integrity.  
Even though our initial hypothesis was that omeprazole would interfere with vacuolar 
acidification of macrophages, acridine orange staining of omeprazole treated macrophages 
revealed that the compound had no effect on vacuolar acidification. 
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Omeprazole has been previously reported to have antibacterial properties on Helicobacter 
[236] and oral streptococci [237] and also anti-parasitic effect on Leishmania [238]. We 
describe a new effect of omeprazole, interference with SPI2-mediated intracellular fitness 
of S. Typhimurium by a novel bacteriostatic mechanism, which does not results from 
increased antimicrobial function of macrophages, but on the contrary in the absence of 
inflammatory activation of infected macrophages. 
 
3.2 PAPER II 
Small-molecular virulence inhibitors show divergent and immunomodulatory effects in 
separate infection models of Salmonella enterica serovar Typhimurium 
In the last decade several screens have been performed to identify chemicals that would 
interfere specifically with expression or function of pathogen-associated virulence factors. 
For Salmonella one such virulence factor that represents an attractive target for interference is 
the T3SS [230]; as already described above, the bacteria possess two individual T3SSs that 
are coded by SPI1 and SPI2, respectively. Studies by our lab [81, 83] revealed two potent 
compounds that interfered with SPI2-mediated intracellular replication of S. Typhimurium in 
RAW264.7 macrophages; the benzimidazole proton pump inhibitor omeprazole and the 
salicylidene acylhidrazide INP0010. As a follow up we set to test and compare the two 
compounds alone or in combination on both virulence-associated traits of S. Typhimurium 
and on inflammatory responses of host, in different infection models. 
In Salmonella research apart from macrophages many infection assays are done using 
epithelial cell lines. These are usually performed to investigate SPI1-mediated bacterial 
invasion but nevertheless Salmonella also undergoes SPI2-dependent intracellular replication 
inside the epithelial cells; moreover, virulence-associated phenotypes such as Sif formation 
have been described and characterized in epithelial cells [119, 136, 137]. Therefore we also 
tested INP0010 and omeprazole in MDCK epithelial cell culture model of infection. 
Surprisingly, omeprazole had no effect on while INP0010 increased the intracellular S. 
Typhimurium growth yield; application of both decreased the up-regulated growth yield 
caused by INP0010 application alone. This implies that the two compounds act in an 
antagonistic manner in this infection setup.  
When tested in RAW264.7 macrophages, omeprazole and INP0010 both decreased the 
intracellular bacterial pool in a dose dependent fashion as previously shown. Application of 
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the two surprisingly tended to abolish the growth reducing effect at a lower concentration 
while at a higher dose it reduced the growth to the same level as when individual compounds 
were applied.  
One of the major differences between epithelial cells and macrophages is the arsenal of 
inflammatory and antimicrobial effectors. In contrast to epithelial cells, macrophages respond 
to bacterial infection by activating inflammatory signalling pathways that lead to production 
of ROS, RNS and pro-inflammatory cytokines. As reported in Paper I [83] omeprazole had 
an anti-inflammatory effect on infected macrophages. Therefore we set to test the same 
parameters, such as iNOS expression, NO and ROS production and release of TNF- also for 
INP0010, alone and in combination with omeprazole. The two virulence inhibitors had 
markedly different effects; opposed to omeprazole, INP0010 up-regulated iNOS expression 
and the levels of NO and TNF- detected 16 hours post infection from the infected cells 
supernatants. Combination of omeprazole and INP0010 reduced the up-regulating effect of 
INP0010. Notably, their effect was not depended on viable S. Typhimurium, since the 
compounds had similar effects also when the cells were only stimulated with LPS. As for 
ROS, omeprazole did not alter the levels, while INP0010 had an up-regulating effect; the 
combination of the two had this time an additive up-regulating effect.  
The interplay between Salmonella and its host has been long studied and there are aspects 
that are still not elucidated. The bacteria are able to circumvent ROS and RNS production by 
various mechanisms, mainly mediated by the expression and function of SPI2. In order to 
investigate the connection between the effects of the two compounds on host cells and on the 
intracellular replication of S. Typhimurium, we included in our infection setup the 
competitive iNOS inhibitor NMMA and the antioxidant and NO scavenger ascorbic acid. As 
expected both chemicals decreased the NO production.  Addition of ascorbic acid or NMMA 
did not have any further effect on the decreased NO production posed by omeprazole and it 
decreased the high levels of NO in INP0010 treated regiments. The bacterial growth yields 
were not affected by NMMA or ascorbic acid in the omeprazole treated infected cells, but in 
the case of INP0010 treatments the addition of NMMA increased the number of intracellular 
bacteria. This suggests that at least partially, the inhibitory effect of INP0010 on the 
intracellular replication of S. Typhimurium is due to its elevating effect on NO production of 
infected cells. 
We also compared the effect of omeprazole and INP0010 on the ability of intracellular GFP-
expressing S. Typhimurium to secrete the hemagglutinin-tagged SseJ SPI2 effector from a 
plasmid. The control infection regiments revealed immunostaining for SseJ around the 
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bacteria and also at dispersed locations in the infected cells. In contrast, in the omeprazole 
treated samples the SseJ was detectable only in the rare cases at clusters of replicating 
bacteria and confined to these clusters. Interestingly, application of INP0010 revealed in 
some cells an elongated bacterial phenotype that did not stain for SseJ. Such a phenomena 
was also previously reported by Rosenberger et al., 2002 [239] in IFN- primed RAW264.7 
macrophages at late stages of the infection (24 hours post infection) and seemed to be 
mediated by MEK kinase signalling and phox [239]. It is hence possible that the elongation 
of the bacteria is due to INP0010-mediated exacerbation of inflammation and oxidative stress 
responses in macrophages. Application of both INP0010 and omeprazole revealed a 
phenotype resembling the application of omeprazole alone, while addition of NMMA on 
INP0010 treated samples restored the control phenotype, thus reinforcing the idea that 
INP0010 mediates its effect on intracellular bacteria through up-regulation of NO.  
We also tested the compounds in a Caenorhabditis elegans infection model. In a liquid-based 
assay the infection with S. Typhimurium results in nematode paralysis and reduced lifespan. 
Application of the individual compounds substantially reduced the paralysis of the worms, 
with INP0010 being more potent than omeprazole. Combination of the two resulted in an 
almost complete abrogation of paralysis in S. Typhimurium infected worms.  
The conclusion of our study is that even though omeprazole and INP0010 are efficient 
reducers of the intracellular numbers of bacteria in the macrophage model of infection, their 
effect is more likely to be the result of independent mechanisms; at least part of INP0010 
effect on bacterial growth is due to up-regulation of NO production in the host cells. The 
effect of the compounds is very much dependent on the cell types used in the infection setup. 
Also, the effect of both compounds seems to be related to the ability of the infected host to 
mount inflammatory and antimicrobial responses. Our study brings in light the importance of 
choosing the right infection models when screening for new virulence inhibitors and the idea 
that the effects of potential candidates on the host should be taken in account and thoroughly 
investigated.  
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3.3 PAPER III 
Thioredoxin 1 participates in the activity of the Salmonella enterica serovar 
Typhimurium pathogenicity island 2 type III secretion system 
Adaptation to the intracellular life-style is a major attribute of Salmonella virulence. Once 
intracellular, the bacteria face great challenges such as oxidative and nitrosative stress, as well 
as the lower pH of the SCV.  As a consequence of the reactive radicals stress the bacteria has 
to maintain a proper surveillance of the redox status of proteins and repair the eventual 
alterations. One of the important reductases that contribute to maintenance of cellular redox 
homeostasis is thioredoxin 1 (TrxA). TrxA catalytically active site consist of two cysteine 
residues that can reduce protein disulphide bonds [240]. Apart from the cysteine related 
catalytical activity, TrxA has also a chaperone function [241]. 
Previous studies by our lab revealed that TrxA contributes to S. Typhimurium virulence in 
macrophages and mice [95]. In the present study we further investigated the role of TrxA in 
bacterial virulence. As intracellular virulence is mediated by SPI2, we set to determine the 
interconnection between TrxA and SPI2.  
When the bacteria were grown in vitro in a minimal medium characterized by low pH, low 
concentration of Mg2+ and phosphate that mimic the conditions that prevail in SCV, we could 
demonstrate that trxA is co-induced with SPI2 and was needed for induction of the SPI2 
T3SS apparatus gene ssaG and for the secretion of the SPI2 effector protein SseJ.  
Next we set to determine the contribution of TrxA to SPI2 activity in infected RAW264.7 
macrophages and MDCK epithelial cells. In order to bypass effects that would relate to 
intracellular replication, but still be able to detect significant numbers of intracellular bacteria, 
we performed the gentamicin protection assay with a higher multiplicity of infection (MOI 
100:1) and restricted the infection to 8 hours, a time that coincides with the beginning of 
intracellular replication [83]. In macrophages, the trxA deficient bacteria showed more 
scattered bacterial ensembles that did not stained for SseJ, as compared to S. Typhimurium 
wild-type infection that revealed perinuclear located intracellular bacteria staining for SseJ. 
Complementation of trxA mutant with a plasmid that codes for wild-type TrxA restored the 
perinuclear location and staining for SseJ. Complementation with a catalytically inactive 
variant of TrxA did not restore the SseJ staining. Yet, when in parallel immunoblotting for 
SseJ of infected cell lysates was performed, complementation with the catalytically inactive 
TrxA gave rise to a small recovery of the SseJ expression as compared to the non-
complemented trxA mutant. Surprisingly, when the same set of bacterial strains was used to 
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infect epithelial cells, the restoration of the wild-type phenotype was noted for both 
catalytically active and inactive TrxA complementation. This implies that the catalytical 
activity of TrxA is particularly important for proper SseJ secretion in macrophages, cells that 
do differ from the epithelial cells in their capability to mount antimicrobial oxidative and 
nitrosative stress, while the non-catalytic function of TrxA significantly contributes to SPI2 
T3SS secretion of effectors such as SseJ in epithelial cells. Indeed, when we let the infection 
to proceed for 16 hours and determined the growth yields of the above-mentioned bacterial 
strains, the catalytically inactive TrxA proficient bacteria were unable to replicate in 
macrophages, while in epithelial cells the replication was restored to a smaller but significant 
level as compared to trxA mutant. 
To investigate whether TrxA and SPI2 contribute to intracellular replication via a shared 
pathway we performed infection of macrophages and epithelial cells with wild-type bacteria, 
an ssaV mutant that act as a SPI2 null mutant, the trxA mutant and a double trxA/ssaV mutant. 
All the mutants revealed a similar degree of impairment in intracellular growth. This made us 
to conclude that TrxA and SsaV contribute through a convergent pathway to intracellular 
replication of S. Typhimurium. 
When trxA and ssaV mutants were used to infect mice by per oral route they display a similar 
level of drastic attenuation in regard to colonization of mLNs, liver and spleen. To be able to 
detect potential more subtle differences in net growth in vivo we also performed competition 
experiments in which the mice were intraperitoneally challenged with 1:1 ratio mixtures of 
the mutant bacterial strains. These experiments revealed that TrxA provided an additional 
fitness in the SPI2-deficient background, while SPI2 did not additionally contribute to 
virulence in a TrxA-deficient background. This implies that SPI2 is inactive in TrxA-
deficient bacteria. As for the catalytically inactive TrxA we also demonstrated that, 
paralleling the results from the epithelial cell line infection, it could partially complement the 
replication defect of the trxA mutant in liver and spleen of BALB/c mice. 
Regarding the potential contribution of TrxA to SPI1 activity, we could not detect a 
significant effect of trxA deletion on SPI1 T3SS-secreted effectors profile or on invasiveness 
of MDCK epithelial cells even in the presence of H2O2. 
The conclusions of Paper III are that both catalytically and non-catalytically activities of 
TrxA are important contributors to S. Typhimurium virulence, depending on the infection 
model used, and that SPI2 and TrxA have a convergent contribution to intracellular 
replication of S. Typhimurium both in vitro and in vivo. 
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3.4 PAPER IV 
Heterogeneity in phagocyte inducible nitric oxide synthase induction in response to 
infection with Salmonella enterica serovar Typhimurium 
S. Typhimurium evokes in infected phagocytes inflammatory responses and production of 
toxic radicals such as ROS and RNS by the enzymes phox and iNOS [134, 135, 206]. On the 
other hand, the bacteria have evolved mechanisms to prevent, evade and repair the damage 
produced by the reactive species. For instance, SPI2 activity seems to protect the intracellular 
bacteria against NO produced by the host cells through interference with iNOS localization 
[134], but in the same time high levels of NO produced by IFN-- stimulated macrophages 
appear to down-regulate SPI2 expression [242]. Moreover, it has been found that RNS 
modify a specific cysteine in the SPI2 activator protein SsrB [229]. At an individual host cell 
level, the outcome of the infection depends on who finally tilts the balance in its favour.  
The most common assays used to assess the levels of iNOS expression and NO production in 
cell culture infection models of Salmonella are immunoblotting to detect iNOS expression 
from infected cell lysates and colorimetric measurements of NO from infected cells 
supernatants using Griess reagent, as described in Paper I and II. Still, the data we can 
extract in these ways will give us an overall picture of the responses at the cell population 
level. Previous unpublished data from our research group revealed that surprisingly the 
infected cells do not stain for iNOS when immunofluorescence microscopy was performed. 
Therefore we pursued to elucidate the activation status of individual cells from a population 
of phagocytes infected with S. Typhimurium and to assess if the heterogeneity of the 
responses is a Salmonella infection specific trait. 
S. Typhimurium infection of RAW264.7 macrophages produced an uneven pattern of iNOS 
expression as analysed by immunofluorescence 16 hours post infection. In this regard, four 
distinct phenotypes were noted; infected cells expressing iNOS, infected cells being iNOS 
negative, uninfected cells being iNOS positive and uninfected cells not expressing iNOS. 
Surprisingly, the vast majority of iNOS responsive cells were not the ones infected, but rather 
uninfected cells neighbouring infected iNOS negative cells. The phenomenon was not 
dependent on the mean of bacterial internalization as both invasive Salmonella and non-
invasive complement-opsonized bacteria resulted in the same pattern of iNOS 
responsiveness, noted as early as 4 hours post infection. A paracrine signalling was excluded 
because physical separation of the cells did not alter the proportion of cells belonging to the 
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four phenotypes. This suggests that the RAW264.7 macrophages might have an intrinsic 
heterogeneity with regard to iNOS responses.  
To investigate if the heterogeneity in iNOS response was related to active virulence-
proficient S. Typhimurium, we performed the infection of cells with wild type bacteria treated 
or untreated with tetracycline to block protein synthesis, the ssaV mutant that act as a SPI2 
mutant and we included also the apathogenic laboratory strain of E. coli TG1. All the above 
mentioned infection regiments resulted in a similar pattern of iNOS resposive cells 
distribution, proving that the capacity of a given cell to mount iNOS is not dependent on 
Salmonella infection as such. Indeed, LPS or IFN- stimulation of uninfected cells resulted in 
a similar heterogeneous pattern of iNOS expression; only when the cells were stimulated with 
a combination of LPS and IFN- the iNOS response was fully restored in almost all cells. 
Pre-stimulation with LPS did not alter the iNOS expression pattern of infected cells, while 
pre-stimulation with IFN- alone or in combination with LPS markedly enhanced the 
proportion of iNOS responsive cells.  
Similar results were obtained also in BMDMs, infected and pre-stimulated as above. When 
we instead used TLR4-/- BMDMs, the iNOS response was completely abrogated for the 
Salmonella infection regiments while E. coli surprisingly generated very few iNOS 
responsive cells. Again, LPS pre-stimulation did not alter the responsiveness of the cells, 
whereas IFN- stimulation did evoke iNOS expression. These results suggest that LPS 
recognition is playing a central role in steering the capability of cells to express iNOS. 
The in vitro results were further paralleled in vivo. Infected mouse livers displayed also a 
heterogeneous pattern of iNOS staining; still, the majority of infected cells were iNOS 
negative, while iNOS expression was mostly detected either in uninfected cells located in the 
vicinity of infected cells or in foci where massive tissue disruption was observed.  
The conclusions from Paper IV are that RAW264.7 macrophages and murine BMDM have 
an intrinsic heterogeneous pattern of iNOS expression that is not dependent on Salmonella 
infection but that relates to TLR4. IFN- stimulation in combination with LPS restores an 
even distribution of iNOS responsive cells in a given population in the absence or presence of 
bacterial challenge. These might have also in vivo implications since a similar pattern of 
iNOS expression was found in S. Typhimurium infected mouse livers. Overall, our results 
underline the need of shifting from gross inspection to individual cell analysis when studying 
host-pathogen interactions.   
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